Key result
Amiodarone demonstrated a better overall response than flecainide and propafenone, with a higher median exposure time (518 vs 218 and 178 days, P<0.001) and fewer cardiovascular adverse reactions.
Why the study?
Does amiodarone improve response rates and reduce adverse drug reactions compared to flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias?
RCT (n=141)
Randomized to various sequences
Yes
Does amiodarone improve response rates and reduce adverse drug reactions compared to flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias?
p-value: p=<0.001
Amiodarone has a more favorable therapeutic profile than flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias, with less tendency to worsen heart failure.
No takes yet. Share an insight, caveat, or question.
Amiodarone may be preferred for complex VA in cardiac disease; extends RCT evidence of superior response and tolerability versus class Ic agents.
A 1992 study conducted an RCT in Complex ventricular arrhythmias and cardiac disease (n=141). Amiodarone vs. Flecainide and propafenone was evaluated on Median exposure time (as an indicator of overall response) (p=<0.001). Amiodarone demonstrated a better overall response than flecainide and propafenone, with a higher median exposure time (518 vs 218 and 178 days, P<0.001) and fewer cardiovascular adverse reactions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: